A study to examine the impact of blockade of the renin-angiotensin system on vascular compliance measurements in subjects with type 2 diabetes mellitus complicated by nephropathy

Trial Profile

A study to examine the impact of blockade of the renin-angiotensin system on vascular compliance measurements in subjects with type 2 diabetes mellitus complicated by nephropathy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2009

At a glance

  • Drugs Irbesartan (Primary) ; Ramipril (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Sep 2009 Status changed from completed to discontinued as reported by ISRCTN: Current Controlled Trials record.
    • 21 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top